Migraine

The Migraine pipeline: 51 tracked drugs, 41 approved for this indication.

41 approved / phase 43 Phase 31 Phase 2/32 Phase 21 US approval withdrawn3 preclinical / unstaged

Compare the share prices of listed companies in Migraine →

Total attributable cost

$104.7B

$6,575/patient

Drug spend

Not yet sourced

How this is calculated ↗

any · US

The Migraine pipeline

← all assets